IQVIA Holdings Inc. Reports Strong Financial Results for Q4 and Full-Year 2024

IQVIA Holdings Inc. (NYSE:IQV), a leading provider of clinical research and healthcare intelligence, announced its financial results for the fourth quarter and full year of 2024 on February 6, 2025. The company demonstrated solid performance, reaffirming its previous guidance for 2025. Ari Bousbib, Chairman and CEO, expressed confidence in the company's trajectory, stating that despite challenges in the contract research organization (CRO) market, IQVIA managed to exceed expectations in several key areas.

In the fourth quarter of 2024, IQVIA reported revenue of $3,958 million, reflecting a 2.3% increase on a reported basis and a 3.0% increase at constant currency compared to the same period in 2023.

GAAP Net Income for the quarter was $437 million, a decrease of 6.8% from the previous year, with GAAP Diluted Earnings per Share (EPS) at $2.42, falling by 4.7% year-over-year. In contrast, Adjusted Net Income was $564 million, up 7.8%, resulting in an Adjusted Diluted EPS of $3.12, reflecting a 9.9% increase.

Adjusted EBITDA for the quarter increased by 3.1% to $996 million.

As of December 31, 2024, R&DS contracted backlog, including reimbursed expenses, stood at $31.1 billion, representing a 4.4% year-over-year growth. The fourth-quarter book-to-bill ratio was reported at 1.20x, contributing to a trailing twelve-month book-to-bill ratio of 1.19x.

For the entire year, IQVIA reported revenue of $15,405 million, marking a 2.8% growth on a reported basis and a 3.4% increase at constant currency. Key segments included:

For the full year, GAAP Net Income was $1,373 million, up 1.1%, while GAAP Diluted EPS reached $7.49, an increase of 2.7%. Adjusted Net Income rose to $2,042 million, up 7.4%, with Adjusted Diluted EPS at $11.13, up 9.1%. Adjusted EBITDA for 2024 was reported at $3,684 million, showing a 3.2% increase.

As of December 31, 2024, IQVIA had $1,702 million in cash and cash equivalents against $13,983 million in debt, resulting in a net debt of $12,281 million. The company’s Net Leverage Ratio stood at 3.33x trailing twelve-month Adjusted EBITDA.

Operating Cash Flow for the fourth quarter was $885 million, while Free Cash Flow amounted to $721 million. For the full year, Operating Cash Flow reached $2,716 million, and Free Cash Flow was $2,114 million, marking growth rates of 26% and 41% year-over-year, respectively.

During Q4 2024, IQVIA repurchased $1,150 million of its common stock, contributing to a total of $1,350 million in share repurchases for the year. The company still has $1,013 million of share repurchase authorization remaining as of December 31, 2024. Notably, on February 5, 2025, the board increased the share repurchase authorization by $2,000 million, bringing the total to $3,013 million.

Looking ahead, IQVIA reaffirmed its 2025 guidance, forecasting revenue growth at constant currency (excluding COVID-related revenue) of 4% to 7%. The company also expects Adjusted EBITDA margin expansion of up to 20 basis points and Adjusted Diluted EPS growth of 5% to 9%. This translates to a full-year revenue outlook of $15,725 million to $16,125 million, with Adjusted EBITDA of $3,765 million to $3,885 million and Adjusted Diluted EPS of $11.70 to $12.10.

IQVIA's robust fourth-quarter and full-year results underscore its resilience and adaptability in a challenging market. With a solid backlog and a strategic focus on growth, the company is well-positioned to navigate the evolving landscape of healthcare and life sciences in 2025 and beyond. Investors will be keen to monitor IQVIA's performance as it executes its growth strategies while managing its financial health.